Clinical Trial Protocol
Iranian Registry of Clinical Trials

07 Jul 2026

Evaluation of the effect of Iranian medicine product, Algro, on the symptoms of patients with covid-19 (Coronavirus 19 disease)

Protocol summary

Study aim
Assessment of the effect of Iranian medicine product, Algro, on the symptoms of patients with covid-19 (Coronavirus 19 disease)

Design
This clinical trial has control group, and with parallel groups, double blinded, randomized, phase 2 to 3 and is performed on 80 patients. Randomization method will be blocked randomization (Quaternary random blocks).

Settings and conduct
Patients in the drug group take the Iranian traditional drug for ten days and 3 times daily In addition to the usual medicines (According to the protocol of the Ministry of Health). Patient in control group use routine treatment and placebo. The study is performed in Baqiyatallah Hospital.

Participants/Inclusion and exclusion criteria
Inclusion criteria: Male or female patients 18 years old and older with COVID-19, positive coronavirus 19 PCR, Ground glass view at low-dose CT scan, Arterial oxygen saturation less than 93%, Consciously completed consent form completed by the patient or the patient's supervisor. Exclusion criteria: History of pulmonary malignancy, History of asthma or COPD, History of Disabling disease or malignancy, Liver or kidney disorders.

Intervention groups
Intervention groups will be two ones.Patients in the intervention group will receive the intervention drug in addition to the routine treatment, but in control group, they will receive placebo in addition to the routine treatment.

Main outcome variables
3D CT Scans, dyspnea, cough, arterial oxygen saturation, PCR, CBC diff

General information

Reason for update

Acronym
Partial Traditional Persian medicine corona study :PTPMCS

IRCT registration information
IRCT registration number: **IRCT20160131026298N3**
Registration date: **2020-04-30, 1399/02/11**
Registration timing: **prospective**

Last update: **2020-11-02, 1399/08/12**
Update count: **1**

Registration date
2020-04-30, 1399/02/11

Registrant information

Name
Ahmad Reza Sharifi Olounabadi

Name of organization / entity
Baqiatallah University of Medical Science, Department of Traditional Iranian Medicine

Country
Iran (Islamic Republic of)

Phone
+98 21 8804 0060

Email address
a-sharifi@shahed.ac.ir

Recruitment status
Recruitment complete

Funding source

Expected recruitment start date
2020-05-04, 1399/02/15

Expected recruitment end date
2020-05-19, 1399/02/30

Actual recruitment start date
empty

Actual recruitment end date
empty

Trial completion date
empty

Scientific title
Evaluation of the effect of Iranian medicine product, Algro, on the symptoms of patients with covid-19 (Coronavirus 19 disease)

Public title
Evaluation of the effect of Iranian medicine product, Algro, on patients with coronavirus 19

Purpose
Treatment

Inclusion/Exclusion criteria

Inclusion criteria:
Male or female patients 18 years old and older with COVID-19 positive coronavirus 19 PCR Ground glass view at low-dose CT scan Arterial oxygen saturation less than 93% Consciously completed consent form completed by the patient or the patient's supervisor

Exclusion criteria:
History of pulmonary malignancy History of asthma or COPD History of Disabling disease or malignancy Liver or kidney disorders

Age
From **18 years** old

Gender
Both

Phase
2-3

Groups that have been masked

- Participant
- Care provider

Sample size
Target sample size: **80**

Randomization (investigator's opinion)
Randomized

Randomization description
Randomization method will be blocked randomization (Quaternary random blocks). Randomization units are individuals. Eighty outpatients referred to the hospital emergency department are randomly assigned to one of the two intervention and control groups. This study is a double-blind method and patients in the intervention group will receive the intervention drug in addition to the routine treatment, but in control group, they will receive the placebo in addition to the routine treatment.

Blinding (investigator's opinion)
Double blinded

Blinding description
Blinding will be performed using a placebo in the control group.

Placebo
Used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee
Ethics committee of Baqiatallah University of Medical Sciences

Street address
Shahid Nosrati Alley, Sheikh Baha'i South Street, Mulla Sadra Street, Vanak Square

City
Tehran

Province
Tehran

Postal code
1435916471

Approval date
2020-03-29, 1399/01/10

Ethics committee reference number
IR.BMSU.REC.1399.038

Health conditions studied

1

Description of health condition studied
COVID-19

ICD-10 code
U07.2

ICD-10 code description
U07.2 COVID-19, virus not identified, COVID-19

Primary outcomes

1

Description
Measurement of cough severity

Timepoint
Day 1 before and at the end of treatment

Method of measurement
Standard cough questionnaire

2

Description
severity of shortness of breath

Timepoint
Day 1 before and at the end of treatment

Method of measurement
Shortness Of Breath With Daily Activity (SOBDA) Questionnaire

3

Description
lung radiologic changes

Timepoint
At beginning and end of the study

Method of measurement
Chest CT scan

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: The medicinal product includes a capsule composed of two herbs(salix ,lambs quarter). The amount of each of these substances in the capsule is 250 mg. The dosage of the product is three capsules a day, which is half an hour before each meal. This product is prepared by Armaghan Sabz Araz Teb Pharmaceutical Company.In this group, common medical drug is also consumed according to the latest protocol of the Ministry of Health.
Category
Treatment - Drugs

2

Description
Control group: Patient in control group use common medicine based on the latest protocol of the Ministry of Health and placebo.
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Baqiyatallah Hospital
Full name of responsible person
REZAMOHTASHAMI; AHMAD REZA SHARIFI OLOUNABADI
Street address
After Sheikh Bahaei avenue, Mulla Sadra Street, Vanak Square
City
Tehran
Province
Tehran
Postal code
1435915371
Phone
+98 21 8805 0436
Email
a-sharifi@bmsu.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Bagheiat-allah University of Medical Sciences
Full name of responsible person
Gholamhosein Alishiri
Street address
Baqiyatallah University, Third Floor, Vice-Chancellor for Research and Technology, Sheikh Bahai St, Mulla Sadra St,Vanak Square
City
Tehran
Province
Tehran
Postal code
1435916471
Phone
+98 21 8755 5250
Email
a-sharifi@bmsu.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
No
Title of funding source
Armaghan Sabz Araz Teb Company
Proportion provided by this source
30
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Other

Person responsible for general inquiries

Contact
Name of organization / entity
Bagheiat-allah University of Medical Sciences
Full name of responsible person
Ahmad Reza Sharifi Olounabadi
Position
Assistant Professor
Latest degree
Ph.D.
Other areas of specialty/work
Traditional Medicine
Street address
Vice-Chancellor for Research and Technology, Third Floor, Baqiyatallah University, Sheikh Bahaei St, Mulla Sadra St, Vanak Square
City
Tehran
Province
Tehran
Postal code
1435916471
Phone
+98 21 8755 5250
Email
a-sharifi@bmsu.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity
Bagheiat-allah University of Medical Sciences

Full name of responsible person
Reza Mohtashami

Position
Assistant Professor

Latest degree
Specialist

Other areas of specialty/work
Internal Medicine

Street address
Baqiyatallah University of Medical Sciences,Sheikh Bahai Street, Molla Sadra Street, Vanak Square

City
Tehran

Province
Tehran

Postal code
1435916471

Phone
+98 21 8755 5250

Email
reza_mohtashami1979@bmsu.ac.ir

Person responsible for updating data

Contact

Name of organization / entity
Bagheiat-allah University of Medical Sciences

Full name of responsible person
Ahmad Reza Sharifi Olounabadi

Position
Assistant Professor

Latest degree
Ph.D.

Other areas of specialty/work
Traditional Medicine

Street address
Baqiyatallah University of Medical Sciences,Sheikh Bahai Street, Molla Sadra Street, Vanak Square

City
Tehran

Province
Tehran

Postal code
1435916471

Phone
+98 21 8755 5250

Email
a-sharifi@bmsu.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available

Study Protocol
Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available

Analytic Code
Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available